Form 4: Celldex Therapeutics SVP and CFO, Samuel Bates Martin, Acquires 81,000 Incentive Stock Options

Samuel Bates Martin, SVP and CFO of Celldex Therapeutics, acquired 81,000 incentive stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Summary

• On June 13, 2024, Samuel Bates Martin, the SVP and CFO of Celldex Therapeutics, Inc., was granted 81,000 incentive stock options.
• The options were granted at an exercise price of $36.43 per share.
• The options vest 25% on June 13, 2025, and the remaining 75% vest quarterly over the subsequent 12 quarters.
• The options expire on June 13, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of incentive stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the biotech industry to attract and retain talent.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for incentive stock option grants.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning management's interests with increasing shareholder value.
• Employees may see the option grant as a sign of confidence in the company's future.

Key Dates